Fig. 5

CD36 inhibition and Nrf2 deficiency counters the protective phenotype of myelin-containing phagocytes. a Experimental setup used to define the impact of CD36 inhibition on the inflammatory and metabolic phenotype of myelin-containing bone marrow-derived macrophages (BMDMs) and microglia. b mRNA expression of Il1b, Nos2, Tnfa, Il6, and Ccl5 in LPS-stimulated BMDMs (n = 6 wells) and microglia (n = 4 wells) treated with vehicle, myelin, and the CD36 inhibitor sulfo-N-succinimidyl oleate (SSO, 100 μM) for 24 h. Dotted line represents control cells stimulated with LPS. c NO concentration in culture supernatants of LPS-stimulated BMDMs (n = 6 wells) and microglia (n = 5 wells) treated with vehicle, myelin, and SSO (100 μM). d mRNA expression of Abca1, Scd1, Cpt1a, and Apoe in LPS-stimulated BMDMs (n = 8 wells) and microglia (n = 4 wells) treated with vehicle, myelin, and the CD36 inhibitor for 24 h. e mRNA expression of Il1b, Nos2, Tnfa, Il6, and Ccl5 in LPS-stimulated BMDMs isolated from Nrf2^−/− mice and wild-type (wt) littermates treated with vehicle and myelin (n = 5 wells). Dotted line represents control cells stimulated with LPS. f mRNA expression of Abca1, Scd1, Cpt1a, and Apoe in LPS-stimulated wt and Nrf2^−/− BMDMs treated with myelin (n = 5 wells). Data are represented as mean ± s.e.m. *p < 0.05, **p < 0.01, and ***p < 0.001